Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Millard

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Theranostics|May 7, 2011
Integrin targeted therapeuticsMelissa Millard, Srinivas Odde, Nouri Neamati
Advanced Drug Delivery Reviews|September 1, 2009
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolismDivya Pathania, Melissa Millard, Nouri Neamati
Plos One|January 26, 2013
Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cellsYumna H Shabaik, Melissa Millard, Nouri Neamati
Journal of Medicinal Chemistry|October 24, 2013
A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancersMelissa Millard, John D Gallagher, Bogdan Z Olenyuk, et al.
Current Pharmaceutical Design|March 12, 2011
Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 updateMelissa Millard, Divya Pathania, Fedora Grande, et al.
Plos One|October 20, 2010
Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activityMelissa Millard, Divya Pathania, Yumna Shabaik, et al.
Blood|February 4, 2010
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actinJingying Xu, Melissa Millard, Xiuhai Ren, et al.
Blood|February 12, 2005
Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathwaysAnat Erdreich-Epstein, Linda B Tran, Orla T Cox, et al.
Journal of the American Chemical Society|July 16, 2013
In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotideYanbin Ji, Subhabrata Majumder, Melissa Millard, et al.
FEBS Letters|December 19, 2023
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinomaYlenia Cicirò, Denise Ragusa, Paloma Tejera Nevado, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Theranostics|May 7, 2011
Integrin targeted therapeuticsMelissa Millard, Srinivas Odde, Nouri Neamati
Advanced Drug Delivery Reviews|September 1, 2009
Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolismDivya Pathania, Melissa Millard, Nouri Neamati
Plos One|January 26, 2013
Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cellsYumna H Shabaik, Melissa Millard, Nouri Neamati
Journal of Medicinal Chemistry|October 24, 2013
A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancersMelissa Millard, John D Gallagher, Bogdan Z Olenyuk, et al.
Current Pharmaceutical Design|March 12, 2011
Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 updateMelissa Millard, Divya Pathania, Fedora Grande, et al.
Plos One|October 20, 2010
Preclinical evaluation of novel triphenylphosphonium salts with broad-spectrum activityMelissa Millard, Divya Pathania, Yumna Shabaik, et al.
Blood|February 4, 2010
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actinJingying Xu, Melissa Millard, Xiuhai Ren, et al.
Blood|February 12, 2005
Endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 involves ceramide metabolic pathwaysAnat Erdreich-Epstein, Linda B Tran, Orla T Cox, et al.
Journal of the American Chemical Society|July 16, 2013
In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotideYanbin Ji, Subhabrata Majumder, Melissa Millard, et al.
FEBS Letters|December 19, 2023
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinomaYlenia Cicirò, Denise Ragusa, Paloma Tejera Nevado, et al.
Pageof 2